Investigational drug · Phase 2
ONO-7703
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pan-tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ONO-7703"
First trial start
2020
Sep 10, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ONO-7703", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pan-tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ONO-7703" as an intervention, largest first.
PfizerPfizer (PFE)
NCT05203172 · 210 participants (planned) · Start Jul 5, 2022 · Primary completion Jul 31, 2029
Drug: Binimetinib; Encorafenib and 11 more · For: Solid Tumors
Sites: Phoenix, Arizona; Atlanta, Georgia; Boston, Massachusetts · 77 sites in all
Ono Pharmaceutical Co., Ltd.Industry
NCT04566380 · 70 participants (planned) · Start Sep 10, 2020 · Primary completion Dec 31, 2027
Drug: ONO-4538; oxaliplatin and 6 more · For: Pan-tumor
Sites: Chiba, Japan; Kashiwa, Japan; Matsuyama, Japan · 44 sites in all
- Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruiting
Pierre Fabre MedicamentIndustry
NCT05195632 · 63 participants · Start Jun 2, 2022 · Primary completion May 27, 2024
Drug: Encorafenib; Binimetinib · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Changchun, China; Changsha, China · 34 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.